The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience.

Authors :: Paci C
Sanguigni S
Carboni T
Gobbato R
Curatola L
Source :: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2003 Oct; Vol. 24 (3), pp. 197-8.
Publication Year :: 2003
Abstract: Since January 2000 we have administered entacapone (200 mg) to 75 patients with severe Parkinson's disease in combination with their routine levodopa dose. At baseline the mean UPDRS (item III) score was 38+/-6. After 3 months of entacapone therapy the patients presented a significant improvement of motor fluctuations; the mean UPDRS score (item III) was 20+/-4. This improvement was also statistically significant after 2 years of entacapone therapy.

Subjects :: Drug Therapy, Combination
Follow-Up Studies
Humans
Levodopa therapeutic use
Motor Activity drug effects
Neurologic Examination
Nitriles
Prospective Studies
Time Factors
Antiparkinson Agents therapeutic use
Catechols therapeutic use
Parkinson Disease drug therapy

Language :: English
ISSN :: 1590-1874
Volume :: 24
Issue :: 3
Database :: MEDLINE
Journal :: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Publication Type :: Academic Journal
Accession number :: 14598085
Full Text :: https://doi.org/10.1007/s10072-003-0128-9

Full Text Access

Tools